Portal de investigación
- Inicio
- Publicaciones
- Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Santini, Valeria
- Platzbecker, Uwe
- Fenaux, Pierre
- Giagounidis, Aristoteles
- Miyazaki, Yasushi
- Sekeres, Mikkael A.
- Xiao, Zhijian
- Van Hoef, Marlies
- Ma, Fei
- Hertle, Sabine
- Ramos, Pedro Marques
- Zeidan, Amer M.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 1340-1342
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Blood AMER SOC HEMATOLOGY
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Santini,V,Platzbecker,U,Fenaux,P,Giagounidis,A,Miyazaki,Y,Sekeres,MA,Xiao,Z et al. Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA:AMER SOC HEMATOLOGY. 2022 p.p. 1340-1342.